CCND2 and pancreatic neoplasm: For instance, miR-373-3p, downregulated in the gemcitabine resistant pancreatic cancer cell line (GEM-PANC-1), targets CCND2 to conspicuously suppress GEM-PANC-1 cells’ proliferation and invasion, boost their apoptosis, and strengthen their sensitivity to gemcitabine [40].